Survie sans rechute : Questions médicales fréquentes
Nom anglais: Disease-Free Survival
Descriptor UI:D018572
Tree Number:N06.850.520.830.998.300
Termes MeSH sélectionnés :
Case-Control Studies
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Survie sans rechute : Questions médicales les plus fréquentes",
"headline": "Survie sans rechute : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Survie sans rechute : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-08",
"dateModified": "2025-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Survie sans rechute"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Analyse de survie",
"url": "https://questionsmedicales.fr/mesh/D016019",
"about": {
"@type": "MedicalCondition",
"name": "Analyse de survie",
"code": {
"@type": "MedicalCode",
"code": "D016019",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.520.830.998"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Survie sans rechute",
"alternateName": "Disease-Free Survival",
"code": {
"@type": "MedicalCode",
"code": "D018572",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Inkyu Kim",
"url": "https://questionsmedicales.fr/author/Inkyu%20Kim",
"affiliation": {
"@type": "Organization",
"name": "WWHEOR, Bristol Myers Squibb, Princeton, NJ, United States."
}
},
{
"@type": "Person",
"name": "Rachel Kerr",
"url": "https://questionsmedicales.fr/author/Rachel%20Kerr",
"affiliation": {
"@type": "Organization",
"name": "Adjuvant Colorectal Cancer Group, University of Oxford, Oxford, UK."
}
},
{
"@type": "Person",
"name": "Mukta Arora",
"url": "https://questionsmedicales.fr/author/Mukta%20Arora",
"affiliation": {
"@type": "Organization",
"name": "Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota."
}
},
{
"@type": "Person",
"name": "Sandhya Gokavarapu",
"url": "https://questionsmedicales.fr/author/Sandhya%20Gokavarapu",
"affiliation": {
"@type": "Organization",
"name": "Resident, Department of Oral and Maxillofacial- Head and Neck Oncology, Shanghai Stomatology key laboratory, Ninth People's Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Risk factors for jaw osteoradionecrosis: a case control study.",
"datePublished": "2022-11-11",
"url": "https://questionsmedicales.fr/article/36383838",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1807-3107bor-2022.vol36.0132"
}
},
{
"@type": "ScholarlyArticle",
"name": "A case-control study on immunologic markers of patients with vitiligo.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244264",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2022.113785"
}
},
{
"@type": "ScholarlyArticle",
"name": "Case-Control Study of Long COVID, Sapporo, Japan.",
"datePublished": "2023-04-12",
"url": "https://questionsmedicales.fr/article/37044126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3201/eid2905.221349"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/37016998",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MBC.0000000000001192"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35875004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2022.913897"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Méthodes épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D004812"
},
{
"@type": "ListItem",
"position": 5,
"name": "Statistiques comme sujet",
"item": "https://questionsmedicales.fr/mesh/D013223"
},
{
"@type": "ListItem",
"position": 6,
"name": "Analyse de survie",
"item": "https://questionsmedicales.fr/mesh/D016019"
},
{
"@type": "ListItem",
"position": 7,
"name": "Survie sans rechute",
"item": "https://questionsmedicales.fr/mesh/D018572"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Survie sans rechute - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Survie sans rechute",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Survie sans rechute",
"description": "Comment évaluer la survie sans rechute ?\nQuels tests sont utilisés pour le diagnostic ?\nQuand commence-t-on à mesurer la SSR ?\nQuels signes indiquent une rechute ?\nQuelle est l'importance du suivi régulier ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Survie sans rechute",
"description": "Quels symptômes peuvent signaler une rechute ?\nLa fatigue est-elle un symptôme de rechute ?\nComment différencier les symptômes de rechute ?\nLes douleurs peuvent-elles indiquer une rechute ?\nLes changements d'appétit sont-ils significatifs ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Survie sans rechute",
"description": "Comment prévenir les rechutes ?\nL'alimentation joue-t-elle un rôle dans la SSR ?\nL'exercice physique est-il bénéfique ?\nLes contrôles médicaux réguliers sont-ils importants ?\nLe soutien psychologique aide-t-il à la SSR ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Survie sans rechute",
"description": "Quels traitements favorisent la SSR ?\nComment la chimiothérapie affecte-t-elle la SSR ?\nLa radiothérapie est-elle efficace pour la SSR ?\nQuels sont les effets secondaires des traitements ?\nComment le suivi post-traitement est-il organisé ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Survie sans rechute",
"description": "Quelles complications peuvent survenir après traitement ?\nComment gérer les effets secondaires ?\nLes complications affectent-elles la SSR ?\nQuels sont les risques de récidive après traitement ?\nLes complications psychologiques sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Survie sans rechute",
"description": "Quels facteurs augmentent le risque de rechute ?\nLe tabagisme influence-t-il la SSR ?\nL'hérédité joue-t-elle un rôle dans la rechute ?\nLe mode de vie influence-t-il la SSR ?\nL'âge est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la survie sans rechute ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La SSR est évaluée par des examens cliniques et des imageries régulières après traitement."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme le scanner ou l'IRM et des marqueurs tumoraux peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quand commence-t-on à mesurer la SSR ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La SSR est généralement mesurée après la fin du traitement actif, souvent 3 à 6 mois après."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une rechute ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la douleur, la fatigue ou des anomalies dans les tests peuvent indiquer une rechute."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi régulier ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le suivi régulier permet de détecter précocement une rechute et d'adapter le traitement."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent signaler une rechute ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur persistante, fatigue accrue, et perte de poids inexpliquée."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme de rechute ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une fatigue persistante peut être un signe de rechute et doit être évaluée."
}
},
{
"@type": "Question",
"name": "Comment différencier les symptômes de rechute ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de consulter un médecin pour évaluer les symptômes et leur origine."
}
},
{
"@type": "Question",
"name": "Les douleurs peuvent-elles indiquer une rechute ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs nouvelles ou persistantes doivent être examinées pour une possible rechute."
}
},
{
"@type": "Question",
"name": "Les changements d'appétit sont-ils significatifs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements d'appétit peuvent être un signe de rechute et nécessitent une attention médicale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les rechutes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, des contrôles réguliers et le respect des traitements prescrits aident à prévenir les rechutes."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la SSR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut renforcer le système immunitaire et aider à la SSR."
}
},
{
"@type": "Question",
"name": "L'exercice physique est-il bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé globale et réduire le risque de rechute."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter rapidement toute rechute potentielle."
}
},
{
"@type": "Question",
"name": "Le soutien psychologique aide-t-il à la SSR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le soutien psychologique peut améliorer la qualité de vie et aider à faire face au stress."
}
},
{
"@type": "Question",
"name": "Quels traitements favorisent la SSR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements comme la chirurgie, la chimiothérapie et la radiothérapie visent à prolonger la SSR."
}
},
{
"@type": "Question",
"name": "Comment la chimiothérapie affecte-t-elle la SSR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie peut réduire la taille des tumeurs et améliorer les chances de SSR."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace pour la SSR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut aider à éliminer les cellules cancéreuses et améliorer la SSR."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue, et immunosuppression, affectant la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment le suivi post-traitement est-il organisé ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le suivi post-traitement inclut des consultations régulières et des examens pour surveiller la SSR."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après traitement ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'infection, la fatigue chronique ou des effets secondaires des traitements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des effets secondaires inclut des soins symptomatiques et un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la SSR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent influencer négativement la survie sans rechute."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de récidive après traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques de récidive varient selon le type de cancer et le traitement reçu, nécessitant un suivi."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications psychologiques comme l'anxiété et la dépression peuvent survenir après le traitement."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de rechute ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme le type de cancer, le stade au diagnostic et l'âge peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la SSR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu qui peut affecter la survie sans rechute."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans la rechute ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de rechute."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il la SSR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de rechute et améliorer la SSR."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut être associé à un risque accru de rechute après traitement."
}
}
]
}
]
}
There are divergences among studies regarding features associated to increased risk of osteoradionecrosis (ORN). Our objective was to identify factors that predispose to the development of ORN of the ...
Vitiligo is a depigmentation skin disease often coexisting with other autoimmune disorders. The prevalence is 0.5-2 % of the world's population. A combination of genetic, environmental and biochemical...
We conducted a cross-sectional survey among SARS-CoV-2-positive persons and negative controls in Sapporo, Japan, to clarify symptoms of long COVID. We collected responses from 8,018 participants, 3,69...
The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev...
A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus...
Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);...
The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...
Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ...
A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch...
Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent...
Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ...
www.chictr.org.cn, identifier: chiCTR2100045986....
Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p...
This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (...
Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ...
Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...
Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden...
Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases...
Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh...
The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...
Psoriasis (PsO) is a chronic inflammatory skin condition, often accompanied by psoriatic arthritis (PsA) and linked to various comorbidities and increased mortality rates. This study aimed to explore ...
Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r...
Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet...
One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%...
Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...
Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs....
Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor...
Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant...
Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...